Advancement in the Skin Treatment to Bring New and Profitable Opportunities for Scar Treatment Market

 

Scar Treatment Market

There are several different types of scar treatment, ranging from the very simple to the highly complex. Chemical peel or microdermabrasion is one of the popular treatments to remove old acne scars and improve the look of wrinkles, discoloration, fine lines, and even sun damage. Non-surgical laser treatment is another option that helps to get rid of the appearance of age spots, and other marks that have appeared due to sun damage or illness. Scar treatment can also be used to treat superficial skin discolorations like birthmarks, age spots, and skin cancers

The high prevalence of skin disease around the globe is driving the growth of scar treatment market. According to the American Academy of Dermatology Association, acne is the most common skin condition in the United States, affecting up to 50 million Americans annually. Around 85 percent of people between the ages of 12 and 24 experience at least minor acne. Atopic dermatitis affects up to 25 percent of children and 2 to 3 percent of adults. Moreover, advancement in skin treatment is another key factor boosting the growth of the scar treatment market. Growing awareness regarding skin treatment among consumers is driving demand for skin treatment products. This is further anticipated to propel the growth of the scar treatment market over the forecast period.

The Asia Pacific has projected to gain significant growth over the forecast period and this is attributed to the increasing focus of manufacturers to introduce innovative scar treatment products for improving efficacy. For instance, in February 2020, Sun Pharmaceutical Industries has launched Absorica LD capsules used for the management of severe nodular acne in the US market

Key Developments:

1.     In August 2020, the U.S. Food and Drug Administration (FDA) approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%). Winlevi is the first acne drug with a new mechanism of action to win regulatory approval in the United States

2.     In July 2019, Dermatix®, a brand of A.Menarini Singapore Pte.Ltd has launched its new acne scar care, Dermatix® Acne Scar. Formulating with Niacinamide (Vitamin B3), Alpha Hydroxy Acids (AHAs), and antioxidants, it delivers a gentle exfoliation to repair acne scars for an overall more even skin tone.

3.     In December 2019, CeraVe has launched a new regimen of products to treat and restore skin. New CeraVe Acne Foaming Cream Cleanser treats acne while Resurfacing Retinol Serum helps reduce the appearance of post-acne marks.

4.     In September 2018, The Skincare Company launched a new line of products to treat acne

5.     In February 2021, Glenmark Pharma has received final approval from the US health regulator for Clindamycin Phosphate Gel, used to treat acne.

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more